The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.

Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...

The shortage of Novo Nordisk’s (NVO) blockbuster weight loss drugs has been resolved, according to the U.S. Food and Drug Administration ...

The Food and Drug Administration said on Friday that the shortage of semaglutide injection products, such as Novo Nordisk's Wegovy, has been resolved. FDA's update led to renewed uncertainty for a ...

In December, the FDA declared that shortages of treatments Zepbound and Mounjaro from another drugmaker, Eli Lilly and Co., also had been resolved. Zepbound is approved to treat obesity and Mounjaro ...

The FDA’s decision will threaten the ability of compounding pharmacies to make far cheaper, unbranded versions of the ...

Unlike other slimming injections, the jab manufactured by US pharmaceutical giant Eli Lilly not only suppresses the appetite ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

WEIGHT loss jabs could raise the risk of a “potentially blinding condition” known as an “eye stroke”, researchers have warned ...

The Food and Drug Administrating announced that to “avoid unnecessary disruption to patient treatment,” the agency does not intend to take ...

Researchers said the study backs up anecdotal evidence from patients and doctors that semaglutide can lead to a sudden loss of longing for alcoholic drinks ...